Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
People living with HIV in the era of antiretroviral therapy (ART) continue to suffer high
rates of neurocognitive disorder. This is a randomized control trial aiming to evaluate
improvement of neurocognitive function after switching efavirenz (EFV) to rilpivirine (RPV).
EFV based regimen is currently the first line ART in Thailand. There are several reports
suggested that HIV-infected patients who took EFV based regimen had poorer neurocognitive
function compared to the comparator. RPV, another first line regimen, has been known to have
less neuropsychiatric side effects. We hypothesized that switching EFV to RPV could improve
neurocognitive function.